Author Archives: admin


Stem Cell Clinic > Articles by: admin

You Are Not Alone When Facing ‘Chemo Brain’ – Curetoday.com

By Stem Cell Treatment

In the summer 2020 edition of HEAL we speak with experts on the very real challenges patients face when confronted with "chemo brain".

For years, many doubted its existence, chalking up the symptoms to old age or another malady. But now, as more survivors are living longer, researchers are better able to study it.

In this issues cover story, Chemo Brain Is Real, we hear from researchers who are investigating cancer-related cognitive impairment, as well as cancer survivors who are living with it. The article also offers strategies that optimize thinking and memory and can help lift that fog.

Through treatment, which included chemotherapy, radiation and two stem cell transplants. For him, however, the biggest challenge was being a young-adult cancer survivor: I survived this thing, and now all of a sudden, Ive got to live the rest of my life. Whos going to want to date me? Can I have kids? Because many of his friends

Also in this issue, readers hear from Ethan Zohn, former professional soccer player and winner of the TV reality show, Survivor: Africa. At age 35, he received a diagnosis of CD20-positive Hodgkin lymphoma. Zohn talks about how his winners mentality helped him.

We hope you not only find the information helpful, but also draw inspiration from the stories of other courageous survivors. As always, thank couldnt relate, Zohn found companionship and comfort through organizations for young adults impacted by cancer.

In addition, a cancer survivor struggling with physical exhaustion ponders whether shed rather be strong of body ... or strong of soul.

Also inside: how yoga and cognitive behavioral therapy can help cancer survivors with insomnia and advice on rebuilding self-esteem after a cancer diagnosis.

As always, thank you for reading.

Continue reading here:
You Are Not Alone When Facing 'Chemo Brain' - Curetoday.com

27th Annual Luau and Legends of Surfing Invitational Set to Make Virtual Waves – UC San Diego Health

By Stem Cell Clinic

Participants gather for a group photo at the 2019 Luau and Legends of Surfing Invitational.

For the first time ever, surfers, scientists, physicians and survivors will come together virtually to support the fight against cancer at the annual Luau and Legends of Surfing Invitational on Aug. 9.

As UC San Diego events are being canceled or postponed because of the coronavirus pandemic, the annual fundraiser has transitioned to a virtual format to allow participants to support the fight against cancer from home.

Instead of surfing the ocean, participants are invited to surf the wave of cancer research as they Crowdsurf for a Cure, helping raise money for research, education and clinical care. All proceeds from the 27th annual Luau and Legends of Surfing Invitational will benefit Moores Cancer Center at UC San Diego Health and contribute to the Campaign for UC San Diego.

As we celebrate the 27th Luau and Legends of Surfing Invitational, it is inspiring to see the local community continue to support the breakthrough discoveries and life-saving treatment developed by Moores Cancer Center, said Dr. Scott M. Lippman, director of Moores Cancer Center at UC San Diego Health. While we cannot join together in person for this years event, cancer does not stop during the COVID-19 pandemic and neither does our commitment to finding new cures and treatments for this life-threatening disease. Thanks to the generous donations raised through the Luau, we can continue to provide our patients with the latest individualized treatment and excellence in patient care that is only available at an academic medical center like ours.

Sandra Dillon and Casey Turk. Photo Courtesy of Sandra Dillon.

The beloved fundraiserwhich has traded tuxedos for wet suits and ballrooms for beach views since its founding in 1993has brought in nearly $10 million for research and helped thousands of cancer patients through clinical trials, new treatments and delivering discoveries. Now, amid nationwide pandemic-related disruptions to the health sector, support towards ending this devastating disease continues to be critical.

For myelofibrosis patient and advocate Sandra Dillon, this support made all the difference in her journey with cancer. When doctors discovered a small lump behind Dillons ribcage in 2004which turned out to be an enlarged spleen, a symptom of myelofibrosisit came completely out of the blue. As a healthy 28-year-old, the last thing she expected was to be diagnosed with an extremely rare cancer with no real treatment options and a median survival rate of five to seven years.

What I thought was my whole life ahead of me was now just a few years, said Dillon, whose doctors tried to manage her symptoms as she slowly got sicker from the disease. I had such a hard time with my diagnosis and my experience. Knowing that there was no treatment that could stop myelofibrosis, I just didn't want to see doctors, be in a hospital or take any more tests. I kind of gave up on medicine in general and figured, Well, Ill just take the time that I've got left and that's all I've got.

Several years later, the trajectory of Dillons life changed completely when she moved to San Diego and was introduced to the team at Moores Cancer Center. Ridden with fear and hesitancy, she made the courageous decision to continue to fight for her life with support from her friends and husband, Casey Turk.

What I found at Moores Cancer Center was the exact opposite of what I was expecting. I was greeted with so much compassion and care at every level, said Dillon, who came to the center in 2011. Initially, I was afraid of being a pin cushion and just a number passing through a system. Instead, I found a home. Moores Cancer Center is a shining light of what treatment and health care can, and should, look like.

Dr. Catriona Jamieson

At Moores Cancer Center, Dillon met physician-scientist Dr. Catriona Jamieson, Deputy Director of Moores, who enrolled her in a clinical trial for a new drug called fedratinib designed to block cancer cell proliferation. The results were amazingin a few months, Dillon was revitalized with newfound energy, less pain and a whole new life.

However, when the promising cancer drug was discarded for safety concerns and its trial pulled, Jamieson and her team were forced to turn to alternate trials and treatments to halt Dillons disease. With the health of multiple patients depleting in the absence of fedratinib, Jamieson worked tirelessly alongside scientist, biotech executive and Moores Cancer Center Board Vice Chair John Hood, who has a doctorate in medical physiology and led early research on the drug, to fight to bring it back. When fedratinib was finally approved by the FDA in 2019, it was the first new therapy approved for myelofibrosis in nearly a decade. It is now available under the brand name Inrebic.

John Hood

Now that I am on the drug, I havent had to have a blood transfusion in over a year. I feel incredible again, said Dillon. What Dr. Jamieson and Hood have accomplished is incredibleits a blessing for me and an amazing testament to what is possible.

During the online fundraiser on Aug. 9, Jamieson and Hood will both be recognized with the Rell Sunn Award, which honors the memory of Rell Kapoliokaehukai Sunn, known as the First Lady of Surfing. Sunn was diagnosed with breast cancer at the age of 32, but rather than submitting to the disease, she lived life to the fullest until passing 15 years later in 1998. The Rell Sunn Award recognizes individuals who have made a difference in the battle against cancer and who embody the Aloha spirit.

This event has had a sustainably positive impact on our relentless drive to deliver new discoveries to the clinic with alacrity, and our unique capacity at Moores Cancer Center to develop personalized cancer stem cell, immunotherapy, and precision-medicine-guided targeted therapies for hopeful patients across economic strata, said Jamieson. To receive this award is such an extraordinary privilege considering that it honors Rell Sunn, a champion Hawaiian surfer who battled breast cancer and was the personification of hope, joy and the spirit of ganbatte, which is the Japanese word for never, ever, ever, give up.

Being honored based on a person like Sunn, by your peers and neighbors, is incredible. I feel very grateful for it, said Hood. I hope what we didfacing down the FDA with a small group in the company and doing everything we can to get it to the patientswould make her proud.

The virtual luau festivities kick off online on Aug. 9 at 5 p.m. Guests can expect to enjoy a program featuring: an address from Chancellor Pradeep K. Khosla, Vice Chancellor for Health Sciences Dr. David Brenner and CEO of UC San Diego Health Patty Maysent, messages from surf legends, Moores Cancer Center leaders, Polynesian dancers, live music and more. Attendees in the local region can also join in by pre-ordering a Dinner and Drinks packagea catered meal and cocktails with options to be picked up or delivered to their home to enjoy during the event. Featured artwork will be presented by Southern California surfer Andy Davis.

The Luau and Legends of Surfing Invitationals Crowdsurf for a Cure is free to register and to attend. Event sponsors include: Cooley LLP; Lina and Christian Waage; Lisa and Mike Rhodes; Valerie Ewell Armstrong and Sam Armstrong; BioMed Realty; ASML; Arey Jones; The Allergan Foundation; and Pfizer. For more information about sponsorship opportunities and event activities, visit the Luau and Legends of Surfing Invitational website. You can also get read more about the Moores Cancer Center at UC San Diego Health.

Gifts made through the 27th annual Luau and Legends of Surfing Invitationals Crowdsurf for a Cure also contribute to the Campaign for UC San Diegoa university-wide comprehensive fundraising effort concluding in 2022. Alongside UC San Diegos philanthropic partners, the university is continuing its nontraditional path toward revolutionary ideas, unexpected answers, lifesaving discoveries and planet-changing impact. For more information, visit campaign.ucsd.edu.

View original post here:
27th Annual Luau and Legends of Surfing Invitational Set to Make Virtual Waves - UC San Diego Health

Global Cell Expansion Market, Forecast to 2025 – Increasing Incidence of Chronic Diseases and Government Investments for Cell-based Research -…

By Stem Cell Medicine

DUBLIN, July 30, 2020 /PRNewswire/ -- The "Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global cell expansion market is projected to reach USD 30.06 billion by 2025 from an estimated USD 14.91 billion in 2020, at a CAGR of 15.1%.

The report segments the cell expansion market based on region (Asia Pacific, Europe, North America, and RoW), product (consumables and instruments), cell type (human cells and animal cells), application (regenerative medicine and stem cell research, cancer and cell-based research and other applications), and end user (research institutes, biotechnology and biopharmaceutical companies, cell banks, and other end users). The report also provides a comprehensive review of market drivers, restraints, and opportunities in the cell expansion market.

Increasing incidence of chronic diseases and government investments for cell-based research are set to drive the cell expansion market

Growth in this market is largely driven by the increasing incidence of chronic diseases, government investments for cell-based research, growing focus on personalized medicine, increasing focus on R&D for cell-based therapies, and increasing GMP certifications for cell therapy production facilities. On the other hand, ethical concerns regarding research in cell biology are expected to limit market growth to a certain extent in the coming years.

By instruments type, the cell expansion supporting equipment accounted for the fasted growing product segment of the cell expansion market

The instruments segment includes cell expansion supporting equipment, bioreactors, and automated cell expansion systems. The cell expansion supporting equipment market includes flow cytometers, cell counters and hemocytometers, centrifuges, and other supporting equipment. They are used in cell culture processes for isolating, culturing, scaling-up, and extracting biological products. These instruments are essential in laboratories and institutes for conducting research and analyzing the cell structure and function for cell therapy research.

By cell type, the human cells segment accounted for the largest share of the cell expansion market

Based on cell type, the cell expansion market is segmented into human cells and animal cells. The human cells segment includes stem cells and differentiated cells. The stem cells segment is further classified into adult stem cells, ESCs, and iPSCs. The human cells segment accounted for the larger share of the cell expansion market majorly due to the increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the growing incidence of diseases such as cancer.

Asia Pacific: The fastest-growing region in the cell expansion market

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing focus of players on emerging Asian markets, increasing incidence of chronic and infectious diseases, rising geriatric population, and government initiatives for infrastructural improvements of healthcare facilities are driving the growth of the cell expansion market in this region.

North America: the largest share of the cell expansion market

North America accounted for the largest share of the cell expansion market. The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, growing geriatric population, and the strong presence of industry players in the region.

Company Profiles

Established Companies

Start-up Companies

For more information about this report visit https://www.researchandmarkets.com/r/5y7cg

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Go here to read the rest:
Global Cell Expansion Market, Forecast to 2025 - Increasing Incidence of Chronic Diseases and Government Investments for Cell-based Research -...

The function of the thymus and its impact on modern medicine – Science Magazine

By Stem Cell Medicine

How the thymus shaped immunology

The function of the thymus was discovered by Jacques Miller in 1961 and laid a foundation for immunology and modern medicine. Until that time, researchers mistakenly believed the thymus merely represented a remnant of defunct lymph tissue, something of an immune cell graveyard. In a Review, Miller recounts the seminal experiments and conceptual thinking that led to uncovering the critical function of the thymus and provides insights that can be learned from those early days. How knowledge of thymus function subsequently spawned the field of T cell biology and the impact it has had on immune cell interactions, vaccination, cancer immunotherapy, and the microbiome are also discussed.

Science, this issue p. eaba2429

Until the 1960s, the thymus had long remained an enigmatic organ with no known function or was considered to be just a graveyard for dying lymphocytes. By contrast, the circulating small lymphocytes found in blood and lymph had been shown in the late 1950s to be long-lived cells able to initiate an immune response when appropriately stimulated by antigen. However, although the thymus was known to be populated with lymphocytes, immunologists had not attributed any immune function to the organ. There were many reasons for this. For example, the cytological hallmarks of an immune response, such as the presence of plasma cells and germinal centers, were not seen in the thymus of healthy animals even after extensive immunization. Thymus lymphocytes, unlike lymphocytes from blood and lymphoid tissues, were unable to mount an immune response on transfer to immunocompromised recipients. Furthermore, thymectomy, which had always been performed in adult animals, was not associated with any immune defects.

In 1961, thymectomy was performed in mice during the immediate neonatal period and revealed the critically important function of the thymus in enabling the development of the immune system. Neonatally thymectomized (NTx) mice were highly susceptible to intercurrent infections, deficient in lymphocytes, unable to reject foreign skin grafts or produce antibody to some (though not all) antigens, and prone to developing certain tumors. There was no major immune defect after adult thymectomy unless the lymphoid tissues had been damaged by total body irradiation. Implanting thymus tissue into NTx mice or irradiated adult thymectomized mice restored immune function. When the thymus graft was taken from a foreign strain, the thymectomized recipients were found to be specifically tolerant of the histocompatibility antigens of the donor. This implied that the thymus was responsible not only for the normal development of immune functions but also for imposing tolerance to the bodys own tissues.

The thymus was shown to seed the lymphoid system with T lymphocytes that migrated to certain discrete areas of the lymphoid tissues and recirculated from the blood through lymphoid tissues, lymph, and back to the bloodstream. T cells exiting the thymus were found to be responsible for killing infected cells and for rejecting foreign tissue grafts. Therefore, T cells could soon be subdivided into subsets based on function, cell surface markers, and secreted products or interleukins. Thymus lymphoid stem cells were subsequently identified, and the epithelial and dendritic cells in the thymus were shown to greatly influence T cell development. They were able to educate T cells to recognize a great diversity of peptide antigens bound to the bodys own markers, major histocompatibility complex molecules, but purged any T cells that strongly reacted against the bodys own self-components. The use of irradiated adult thymectomized mice showed that T cells were not the precursors of antibody-forming cells but were essential to help, through some type of collaboration, other lymphocytes originating in bone marrow (B cells) to respond to antigen by producing antibody.

The discovery of thymus function and of T and B cell collaboration was a major immunological milestone because it not only opened up the field of immune cell interactions but also changed the course of immunology and medicine. It promoted the need for all immune phenomena, for example, memory, tolerance, autoimmunity, and immunodeficiency, as well as inflammatory and immunopathological disease conditions, to be reassessed in terms of the role played by the two distinct sets of lymphocytes and their subsets. We now know that T cells are involved in the entire spectrum of tissue physiology and pathology and even in situations not considered to be bona fide immunological conditions, such as tissue repair, dysbiosis, eclampsia, senescence, and cancer.

Hemopoietic stem cells originating in the yolk sac, fetal liver, or bone marrow migrate through the blood to the thymus, where they differentiate into T lymphocytes. Others differentiate within the bone marrow in mammals, or the bursa of Fabricius in birds, to produce B cells. Mature T and B cells circulate in the blood and lymph and colonize the T and B cell compartments of the lymphoid tissues.

The lymphoid system is intimately involved in immunological processes. The small lymphocyte that circulates through blood into lymphoid tissues, then through the lymph and back to the blood through the thoracic duct, is able to initiate immune responses after appropriate stimulation by antigen. However, the lymphocytes found in the thymus are deficient in this ability despite the fact that the thymus plays a central role in lymphocyte production and in ensuring the normal development of immunological faculty. During embryogenesis, lymphocytes are present in the thymus before they can be identified in the circulation and in other lymphoid tissues. They become educated in the thymus to recognize a great diversity of peptide antigens bound to the bodys own marker antigen, the major histocompatibility complex, but they are purged if they strongly react against their own self-components. Lymphocytes differentiate to become various T cell subsets and then exit through the bloodstream to populate certain areas of the lymphoid system as peripheral T lymphocytes with distinct markers and immune functions.

View original post here:
The function of the thymus and its impact on modern medicine - Science Magazine

AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients – Xconomy

By Stem Cell Medicine

Xconomy Boston

AlloVir is the latest biotech company to go public, raising about $276.3 million to pull its cell therapies off the shelf and run multiple clinical trials testing them in stem cell and organ transplant patients.

On Thursday, Cambridge, MA-based AlloVir (NASDAQ: ALVR)priced its offering of 16.25 million shares at $17 apiece, the midpoint of its targeted $16 to $18 per share price range. The company was able to sell more shares than it planned, boosting the size of the stock offering from the initial target of 14.75 million shares. AlloVir shares opened at $20 apiece, up 17.6 percent from the IPO price.

AlloVir is developing cell therapies intended to treat and prevent viral infections in transplant patients. These patients have weak immune systems that make them particularly susceptible to infection. The standard of care includes antiviral drugs. But sometimes these drugs arent enough to stop viruses, and these treatments can damage the kidneys. Instead of taking viruses head on, AlloVirs cell therapies are intended to restore the ability of a patients immune system to tackle them.

The AlloVir cell therapies are called virus-specific T cells, or VSTs. The process for making a VST therapy is similar to the way that CAR-T cancer treatments are produced. Immune cells are removed from the body and multiplied in a lab. But unlike CAR-T therapies, AlloVirs process doesnt engineer the cells in any way. The AlloVir cell therapies also dont start with a patients own immune cells. The allogeneic approach uses the T cells of healthy people who have already been exposed to viruses. That exposure is expected to be enough get these cells to go after these viruses after the therapy has been infused into a transplant patient.

Once produced, AlloVirs therapies can be stored and pulled off the shelf for use as needed. Speaking to Xconomy last year, companyco-founder and Chief Scientific Officer Ann Leen, an immunologist at the Baylor College of Medicine, likened the process to growing an immune system outside of the body, and giving it to transplant patients at the first sign of infection.

The most advanced AlloVir product candidate, Viralym-M, is a VST that targets five viruses: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company is testing the cell therapy as a treatment for both stem cell transplant patients and organ transplant patients.

So far, Viralym-M has been evaluated in a Phase 2 clinical trial. According to the prospectus, the experimental therapy was given to 58 stem cell transplant patients whose infections had not responded to earlier antiviral treatments. The study was not designed to show statistical significance or that the VST was superior to antivirals. The proof-of-concept clinical trial was intended to show how the therapy works and whether it can be given safely.

In the study, 93 percent54 patientsresponded to the therapy in some way. A complete response, defined as the viral load returning to the range found in healthy people and resolution of the signs and symptoms of infection, was observed in 17 patients. Another 37 patients showed a partial response, defined as the viral load falling by half.

The therapy was well-tolerated by patients. The serious complications and patient deaths in the study were deemed unrelated to the AlloVir therapy. Graft-versus-host-disease, an immune response that is a known risk of stem cell transplants, was reported in 14 patients. A total of 23 patients in the study died. Preliminary clinical trial data were published in the Journal of Clinical Oncology in 2017.

There are no cell therapies approved for use in the US or Europe for treating or preventing the viral infections that AlloVir is targeting. But the company faces potential competition from South San Francisco-based Atara Biotherapeutics (NASDAQ: ATRA), which has advanced an allogeneic cell therapy called tabelecleucel to Phase 3 testing. That study is evaluating the therapy as a treatment for stem cell and organ transplant patients who develop Epstien-Barr viral infection along with post-operative lymphoproliferative disease, a known complication of transplant procedures.

AlloVir was founded in 2013 based on technology developed in Leens research lab, which is part of the Center for Cell and Gene Therapy at Baylor. The company, which was initially named ViraCyte, is led by CEO David Hallal. Hallal is also the chief executive of ElevateBio, a Waltham, MA-based company that provides manufacturing services for cell and gene therapy companies and also invests in them. ElevateBio is AlloVirs largest institutional shareholder, holding a 21.9 percent post-IPO stake, according to the prospectus. Prior to the IPO, the filing shows that AlloVir had raised $156.3 million, including a $12o million Series B round last year.

According to the prospectus, AlloVir plans to use the IPO cash to advance Viralym-M to a Phase 3 study testing it against hemorrhagic cystitis, inflammation of the bladder that is a virus-associated complication faced by stem cell transplant patients. The drug will also be tested in separate late-stage studies in cytomegalovirus and adenovirus. About $98 million is planned for those Phase 3 tests.

Another $83 million is earmarked for Phase 2 tests of Viralym-M. Those tests will cover the prevention of multiple viral infections in stem cell transplant patients, treating BK virus infection in kidney transplant patients, and treating cytomegalovirus infections in solid organ transplant patients.

The IPO cash will also support two respiratory virus programs. ALVR106 is being developed to treat respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus. That VST is expected to start Phase 1 tests in the second half of this year. The other respiratory virus program, ALVR109, is in development as a treatment for infection by the novel coronavirus SARS-CoV-2. The company plans to advance that program to Phase 1/2 testing.

Image: iStock/Jay_Zynism

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan@xconomy.com.

Here is the original post:
AlloVir's IPO Raises $276M to Test Cell Therapies in Transplant Patients - Xconomy

Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems – Business Wire

By Stem Cell Medicine

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets. The Hong Kong Red Cross BTS is the only public institution providing blood to all hospitals, public and private, in Hong Kong.

Following a thorough selection process, we are pleased to be selected by the Hong Kong Red Cross BTS to supply INTERCEPT Blood System for platelets, said Pascal Maillard, Cerus vice president of commercial operations for the Asia Pacific region. INTERCEPT for platelets provides a robust, broad-spectrum inactivation, reducing the risks of transfusion-transmitted infections and thereby enhancing patient care.

This is an important contract for Cerus, continued Maillard. The Hong Kong Red Cross BTS is a member of the influential Asia Pacific Blood Network (APBN) and a key opinion leader globally. This tender award presents a unique opportunity to expand the use of INTERCEPT in Asia-Pacific, a region that represents a significant market growth opportunity for Cerus.

The tender award builds upon the prior experience of the Hong Kong Red Cross BTS with the INTERCEPT Blood System for platelets. The Hong Kong Red Cross BTS, in collaboration with the Queen Mary Hospital, conducted a clinical study successfully transfusing INTERCEPT treated platelet components prepared without leukocyte reduction, without bacterial screening, and without gamma irradiation to allogeneic Hematopoietic Stem Cell Transplant (HSCT) patients (Sim, Tsoi et al. 2019).

This innovative study conducted by the Hong Kong Red Cross BTS and Queen Mary Hospital has the potential to change how patients are supported with platelet transfusions, said Dr. Laurence Corash, Cerus chief scientific officer. The study indicated that INTERCEPT treatment could potentially replace leukocyte filtration, a common practice to reduce the incidence of febrile transfusion reactions, alloimmunization, and cytomegalovirus (CMV) infection. The INTERCEPT platelet system has already demonstrated widespread replacement of bacterial screening, gamma irradiation, and CMV serology in the EU and U.S.

The Hong Kong Red Cross BTS recently completed renovations and is a state-of-the-art facility that manufactures approximately 40,000 platelet doses per year, a portion of which will be treated with INTERCEPT.

Sim, J., W. C. Tsoi, et al. (2019). "Transfusion of pathogen-reduced platelet components without leukoreduction." Transfusion 59(6): 1953-1961.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the worlds blood supply and aims to become the preeminent global blood products company. Based in Concord, California, our employees are dedicated to deploying and supplying vital technologies and pathogen-protected blood components for blood centers, hospitals and ultimately patients who rely on safe blood. With the INTERCEPT Blood System, we are focused on protecting patients by delivering the full complement of reliable products and expertise for transfusion medicine. Cerus develops and markets the INTERCEPT Blood System and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. For more information about Cerus, visit http://www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Forward Looking Statements

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus belief that the INTERCEPT Blood System has the potential to change how patients are supported with platelet transfusions and to potentially replace leukocyte filtration, and other statements that are not historical facts. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks related to Cerus ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction and the INTERCEPT Blood System is safe, effective and economical; the risk that applicable regulatory authorities and healthcare practitioners may disagree with Cerus interpretations of the data from its clinical studies; as well as other risks detailed in Cerus filings with the Securities and Exchange Commission, including Cerus Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 5, 2020. In addition, to the extent that the COVID-19 pandemic adversely affects Cerus business and financial results, it may also have the effect of heightening many of the other risks and uncertainties described above. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

See more here:
Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems - Business Wire

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – Cambridge Network

By Stem Cell Treatment

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and licence agreement with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620) and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avactas neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future global pandemics.

Respiratory diseases such as COVID-19 can cause serious damage to the lungs as a consequence of over-activation of the patient's immune system, resulting in cytokine release syndrome that can potentially lead to multiple organ failure and death. Stem cell therapies offer a very promising approach to repair the damage to lung tissues in these pulmonary diseases by controlling the immune balance.

AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong Pharmaceutical, is developing a novel class of mesenchymal stem cell (MSC) treatments that are engineered to also produce Affimer therapies in the patient at the site of action.

The expansion of the agreement between Avacta, Daewoong Pharmaceutical and AffyXell announced today extends the scope of the partnership to include Affimer molecules that target viruses, such as coronaviruses, in order to develop therapies that repair the lung damage caused by COVID-19 whilst also producing neutralising Affimer molecules to prevent the progression of the disease.

AffyXell will engineer mesenchymal stem cells to express SARS-COV-2 neutralising Affimer molecules in order to develop treatments for seriously ill COVID-19 patients, and will also prepare for rapid development of next-generation stem cell therapies for future infectious respiratory disease outbreaks.

Dr Alastair Smith, Chief Executive of Avacta Group commented: I am very pleased to have extended our collaboration and licence agreement with Daewoong Pharmaceutical to include the SARS-COV-2 neutralising Affimer molecules for the treatment of COVID-19 and to create the potential to respond very rapidly in future to global virus threats.

"AffyXell will address the need over the coming years for advanced stem cell therapies to treat lung damage caused by cytokine release syndrome suffered by COVID-19 patients and, at the same time, help prevent disease progression in these patients through the action of a neutralising Affimer therapy.

"More broadly, one of the key areas of unmet clinical need that AffyXell can address with its next-generation mesenchymal stem cell therapies is acute pulmonary diseases such as COPD and acute respiratory distress syndrome. We, and our partners in South Korea, are very excited by the potential to develop life improving treatments for patients with these serious respiratory diseases as well as COVID-19.

"I look forward to further updating the market on progress in our ground-breaking programmes with AffyXell in due course, and on progress with our COVID-19 diagnostics programmes shortly.

Seng-ho Jeon, CEO of Daewoong Pharmaceutical and AffyXell Therapeutics, commented: It is very encouraging that AffyXell now has the opportunity to expand the application of its next-generation stem cell platform technology to target viruses. The SARS-COV-2 neutralising Affimer to be developed in combination with AffyXells cell and gene technology is expected to be an innovative solution for COVID-19 patients suffering cytokine release syndrome.

"Daewoong has been also conducting several research programs and clinical trial for COVID-19. As the COVID-19 crisis has caused great difficulties worldwide, we will continue to focus our efforts to develop a novel therapeutic agent for COVID-19.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

Read the rest here:
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy - Cambridge Network

Global Cell Isolation/Cell Separation Market Industry Analysis and Forecast (2019-2026), By-Product, Cell Type, Cell Source, Technique, Application,…

By Embryonic Stem Cells

Global Cell Isolation/Cell Separation Market was valued US$ XX Bn in 2018 and is expected to reach US$ 17.92 Bn by 2026, at a CAGR of around XX % during a forecast period.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/34136

The report covers all the trends and technologies playing a major role in the growth of the Cell Isolation/Cell Separation market during the forecast period. It highlights the drivers, restraints, and opportunities expected to influence the market growth during 2019-2026.

Some of the market drivers for the cell isolation/cell separation market are increasing incidences & prevalence of chronic diseases with the aging population, technological advancement in cell isolation, growing demand for bio-pharmaceuticals, personalized medicine, and increasing stem cell research. Cell isolation or separation is a tool used to sort cells into a specific population from a heterogeneous group of cells without contamination. The use of cell isolation techniques helps to open the door of cell-based therapies and thereby improve the quality of treatment and clinical outcome.

However, the ethical issues regarding the isolation of embryonic stem cells and the high cost of cell separation instruments are expected to restrict the growth of this market during the forecast period.

Based on cell type, the human cell segment is expected to register a major revenue share in the cell isolation/cell separation market globally. Owing to increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the high frequency and growing incidence of diseases such as cancer.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/34136

Based on the product, the consumables segment is expected to witness the fastest growth during the forecast period. Because of the increasing investments by companies to develop advanced products and the rising government initiatives for improving cell-based research are driving the growth of this segment.

North America region is expected to grow at a XX % rate of CAGR during the forecast period owing to increasing government support for cancer and stem cell research, the expanding biotechnology and biopharmaceutical industries and the increasing prevalence of chronic and infectious diseases in which cell isolation is required for diagnosis and treatment. Which results in, increase in demand for cell isolation products.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Cell Isolation/Cell Separation Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in Global Cell Isolation/Cell Separation Market. Scope of the Global Cell Isolation/Cell Separation Market

Global Cell Isolation/Cell Separation Market, By Product

Consumables o Reagents, Kits, Media, and Sera o Beads o Disposables Instruments o Centrifuges o Flow Cytometers o Magnetic-activated Cell Separator Systems o Filtration Systems Global Cell Isolation/Cell Separation Market, By Cell Type

Human Cells o Differentiated Cells o Stem Cells Animal Cells Global Cell Isolation/Cell Separation Market, By Cell Source

Adipose Tissue Bone Marrow Cord Blood/Embryonic Stem Cells Global Cell Isolation/Cell Separation Market, By Technique

Centrifugation-based Cell Isolation Surface Marker-based Cell Isolation Filtration-based Cell Isolation Global Cell Isolation/Cell Separation Market, By Application

Biomolecule Isolation Cancer Research Stem Cell Research Tissue Regeneration & Regenerative Medicine In Vitro Diagnostics Global Cell Isolation/Cell Separation Market, By End user

Research Laboratories and Institutes Hospitals and Diagnostic Laboratories Biotechnology and Biopharmaceutical Companies Other End Users Global Cell Isolation/Cell Separation Market, By Region

North America Europe Asia Pacific Middle East & Africa South America Key players operating in the Global Cell Isolation/Cell Separation Market

Thermo Fisher Scientific Beckman Coulter Becton, Dickinson and Company GE Healthcare Merck KgaA Miltenyi Biotech pluriSelect STEMCELL Technologies Inc. Terumo BCT Bio-Rad Laboratories Inc.

MAJOR TOC OF THE REPORT

Chapter One: Cell Isolation/Cell Separation Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Isolation/Cell Separation Market Competition, by Players

Chapter Four: Global Cell Isolation/Cell Separation Market Size by Regions

Chapter Five: North America Cell Isolation/Cell Separation Revenue by Countries

Chapter Six: Europe Cell Isolation/Cell Separation Revenue by Countries

Chapter Seven: Asia-Pacific Cell Isolation/Cell Separation Revenue by Countries

Chapter Eight: South America Cell Isolation/Cell Separation Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Isolation/Cell Separation by Countries

Chapter Ten: Global Cell Isolation/Cell Separation Market Segment by Type

Chapter Eleven: Global Cell Isolation/Cell Separation Market Segment by Application

Chapter Twelve: Global Cell Isolation/Cell Separation Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Isolation/Cell Separation Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-isolation-cell-separation-market/34136/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Link:
Global Cell Isolation/Cell Separation Market Industry Analysis and Forecast (2019-2026), By-Product, Cell Type, Cell Source, Technique, Application,...

Celsius Therapeutics, Twist Bioscience, And More: News From July 2020 – Bio-IT World

By Stem Cell Clinic

July 30, 2020 |July featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Celsius Therapeutics, Twist Bioscience, and more.

Celsius Therapeuticsannounced the signing of three collaboration agreements with the University of Oxford, Cleveland Clinic, and the LMU University Hospital Munich. In each agreement, Celsius will partner with leading academic scientists to access patient tissue samples and apply its proprietary single-cell genomics platform and machine learning capabilities to discover new insights into inflammatory bowel disease (IBD). Under these collaborations, Celsius will evaluate a large number of longitudinal (both pre- and post-treatment) samples, including biopsies from patients who respond to or fail anti-TNFa therapy (University of Oxford); Crohns disease patients who develop disease recurrence following intestinal resection (Cleveland Clinic); and children with very early onset IBD (LMU University Hospital Munich). Celsius will integrate single-cell RNA sequencing data from these samples with clinical data provided by its partners to identify novel drug targets and patient stratification approaches for specific patient subsets. Under the terms of each agreement, Celsius retains the ability to incorporate both the de-identified clinical information and longitudinal single-cell genomics data generated from these studies into its large and continuously growing database. Celsius plans to combine the knowledge generated by these agreements with other work using its single-cell genomics and machine learning algorithms to elucidate this complicated disease biology. Further, Celsius will combine these insights with orthogonal data sets derived from functional genomics and other approaches to verify biological mechanisms and validate potential drug targets. Press release

Twist Bioscienceannounced a partnership withTakeda for access to proprietary phage display libraries for the discovery, validation and optimization of antibodies in Takedas pipeline of biologics for oncology, rare diseases, neuroscience, and gastroenterology. Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will license to Takeda its Library of Libraries, a panel of synthetic antibody phage display libraries derived only from sequences that exist in the human body. Together, the companies will work to discover, validate and optimize new antibody candidates. In return, Takeda will pay Twist annual technology licensing fees, as well as milestones and royalties for all compounds discovered from the Twist phage display libraries. We look forward to applying our unique ability to generate robust, diverse and cutting-edge libraries together with Takedas deep insight into therapeutic drug discovery and development to truly forge new frontiers in bringing personalized therapies to patients worldwide, Emily M. Leproust, CEO and co-founder of Twist Bioscience, said in an official statement. Press release

LabVantage Solutionsannounced that the newly-released 8.5 edition of its LabVantageplatform offers a fully integrated Scientific Data Management System (SDMS). LabVantage SDMS ensures security and control against data loss or modification. The optional SDMS seamlessly interfaces with all elements of the LabVantage platform, including LIMS (laboratory information management system), ELN (electronic laboratory notebook), and LES (laboratory execution system). LabVantage 8.5 also includes a new and comprehensive Configuration Management and Transfer (CMT) feature for greater LIMS administration productivity and better control, along with a number of enhancements that make the LabVantage ELN easier to use. During these challenging times, we are especially proud to release LabVantage 8.5, which represents a major advance reflecting our commitment to making the advantages of digital transformation fully accessible to our customers, said John Heiser, CEO of LabVantage, in a press release. LabVantage 8.5s fully integrated SDMS is specifically designed for the LabVantage platform and provides major benefits to laboratory managers, with the aim of making their operations more efficient, productive, and secure. Our user-friendly, all-in-one SDMS offers seamless, continuous data integrity. Importantly, it allows managers to secure all of their data, not just the final results. The integrated SDMS automatically collects and protects all instrument and other relevant laboratory data as it is generated, which provides a rich informatics and analytical resource that enables better lab management, improved quality, and enhanced security. Full integration means that all relevant lab-generated data is collected automatically and rapidly made available to laboratory staff. Importantly, integration ensures data integrity and security by eliminating the need to transfer data between system components or to leave it with the instrument system, typically a weak link in the process. Press release

The Josep Carreras Leukaemia Research Institutehas created the OneChain Immunotherapeutics (OCI)spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis. The spin-off is being funded initially through a round of seed capital provided by Invivo Ventures, the Ministry of Industry, through CDTI-Innvierte, and the Josep Carreras Foundation, and it clearly makes the case for bringing the research carried out by Dr. Pablo Menndez's group closer to patients. Dr. Mendez is an ICREA research professor and the scientific director at the Josep Carreras Leukaemia Research Institute's Hospital Clnic-UB Campus. "OCI is the vehicle that will enable us to take all the work we have been doing over all these years and apply it to clinical use, Dr. Menndez said in an official statement. At the academic level it is very complicated to develop these strategies and manage all the regulatory mechanisms associated with the development of a product. OCI will enable us to carry out all the necessary steps so that all our knowledge can be available to patients." Press release

VantAIand TARA Biosystemsannounced the launch of a biology-driven, AI-enabled collaboration for accelerated cardiac drug development. The partnership will leverage TARAs state-of-the-artin vitrohuman biology models and VantAIs leading computational drug discovery capabilities to identify and develop new therapies to fight cardiac disease. Combining the power of VantAIs machine learning-enabled gene-disease mapping techniques with the rich, high-fidelity phenotypic data generated from TARAsin vitrohuman cardiac disease models, TARA and VantAI will identify novel drug targets linked to cardiac disease. Then, the team will use VantAIsin silicoplatform to produce novel molecules that effectively modulate these targets, many of which have been previously considered undruggable. VantAIs platform will prioritize modality strategies and use generative approaches to design precise chemistry that is effective while also displaying favorable pharmaceutical properties. The functional response of these novel molecules will then be evaluated in TARAs induced pluripotent stem cell-derived human cardiac tissue models, which include a repertoire of healthy, gene-edited, patient-derived, and drug-induced phenotypes of human disease. The TARA models represent a highly versatile platform for capturing robust physiologic endpoints of human cardiac function, including contractility, electrophysiology, calcium signaling, structure, as well as genomic, proteomic, and metabolic profiles. These comprehensive experimental results will be fed back to VantAIsin silicoplatform to both power further refinement of lead candidates and expand the VantAI-TARA joint data graph view of cardiac disease systems. Press release

Read more from the original source:
Celsius Therapeutics, Twist Bioscience, And More: News From July 2020 - Bio-IT World

Global Covid-19 impact on Stem Cell Storage Market Insights and Upcoming Trends to Forecast till 2025| CCBC, CBR, ViaCord, Esperite, Vcanbio – Owned

By Stell Cell Research

Global Stem Cell Storage Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)

Chicago, United States: The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Stem Cell Storage Market. It includes Porters Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Stem Cell Storage Market. We have provided deep analysis of the vendor landscape to give you a complete picture of current and future competitive scenarios of the global Stem Cell Storage market. Our analysts use the latest primary and secondary research techniques and tools to prepare comprehensive and accurate market research reports.

Final Stem Cell Storage Report will add the analysis of the impact of COVID-19 on this Market.

Stem Cell Storage Market competition by top manufacturers/Key player Profiled: CCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell, Stemade Biotech

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Stem Cell Storage Market:

Global Stem Cell Storage Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during the 2021-2026. The report analyses the global Stem Cell Storage market, the market size and growth, as well as the major market participants. The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Segmentation by Product:

Umbilical Cord Blood Stem Cell Embryonic Stem Cell Adult Stem Cell Other

Segmentation by Application:

Diseases Therapy Healthcare

Competitive Analysis:

Global Stem Cell Storage Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Stem Cell Storage Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report: The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Stem Cell Storage Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The report offers in-depth assessment of the growth and other aspects of the Stem Cell Storage market in important countries (regions), including:

North America(United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

For Customised Template PDF Report: https://www.reporthive.com/request_customization/2291919

Table of Contents

Report Overview:It includes major players of the global Stem Cell Storage Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Stem Cell Storage Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Stem Cell Storage Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Stem Cell Storage Market by application, it gives a study on the consumption in the global Stem Cell Storage Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Stem Cell Storage Market are profiled in this section. The analysts have provided information about their recent developments in the global Stem Cell Storage Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Stem Cell Storage Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Stem Cell Storage Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Stem Cell Storage Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us: Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

See the original post:
Global Covid-19 impact on Stem Cell Storage Market Insights and Upcoming Trends to Forecast till 2025| CCBC, CBR, ViaCord, Esperite, Vcanbio - Owned

→←